Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Fabian Knörr; Kim P.J. Schellekens; Reineke A. Schoot; Judith Landman-Parker; Heiko Manuel Teltschik; Jan Förster; Amambay Riquelme; Alwin D.R. Huitema; Natasha K.A. van Eijkelenburg; Auke Beishuizen; C. Michel Zwaan; Wilhelm Woessmann; Jasper van der Lugt

doi:10.3324/haematol.2022.281896

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Fabian Knörr
, Kim P.J. Schellekens
, Reineke A. Schoot
, Judith Landman-Parker
, Heiko Manuel Teltschik
, Jan Förster
, Amambay Riquelme
, Alwin D.R. Huitema
, Natasha K.A. van Eijkelenburg
, Auke Beishuizen
, C. Michel Zwaan
, Wilhelm Woessmann
, Jasper van der Lugt

Research output: Contribution to journal › Letter › Academic › peer-review

3 Citations (Scopus)

2 Downloads (Pure)

Original language	English
Pages (from-to)	1442-1446
Number of pages	5
Journal	Haematologica
Volume	108
Issue number	5
DOIs	https://doi.org/10.3324/haematol.2022.281896
Publication status	Published - May 2023

Access to Document

10.3324/haematol.2022.281896Licence: CC BY-NC

10908-Article Text-79834-2-10-20230427Final published version, 1.89 MBLicence: CC BY-NC

Cite this

Knörr, F., Schellekens, K. P. J., Schoot, R. A., Landman-Parker, J., Teltschik, H. M., Förster, J., Riquelme, A., Huitema, A. D. R., van Eijkelenburg, N. K. A., Beishuizen, A., Zwaan, C. M., Woessmann, W., & van der Lugt, J. (2023). Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica, 108(5), 1442-1446. https://doi.org/10.3324/haematol.2022.281896

@article{de73648f10944e56af67c7bfd156390b,

title = "Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma",

author = "Fabian Kn{\"o}rr and Schellekens, \{Kim P.J.\} and Schoot, \{Reineke A.\} and Judith Landman-Parker and Teltschik, \{Heiko Manuel\} and Jan F{\"o}rster and Amambay Riquelme and Huitema, \{Alwin D.R.\} and \{van Eijkelenburg\}, \{Natasha K.A.\} and Auke Beishuizen and Zwaan, \{C. Michel\} and Wilhelm Woessmann and \{van der Lugt\}, Jasper",

note = "Funding Information: KS, RS, AH, NvE, CMZ, AB and JvdL received institutional funding from Pfizer. FK, HT, AR, JF, JLP and WW have no conflicts of interest to declare. Funding Information: Pfizer Inc. provided funding and a clinical research collaboration to implement the CRISP trial. The CRISP trial was sponsored by Erasmus MC Sophia Children{\textquoteright}s Hospital, Department of Pediatrics, Rotterdam, The Netherlands, and was funded by the Erasmus MC Vriendenfonds Funding Information: Pfizer Inc. provided funding and a clinical research collaboration to implement the CRISP trial. The CRISP trial was sponsored by Erasmus MC Sophia Children{\textquoteright}s Hospital, Department of Pediatrics, Rotterdam, The Netherlands, and was funded by the Erasmus MC Vriendenfonds (now Erasmus MC Foundation), Pfizer and Go4Children to CMZ. The NHL-BFM Registry 2012 was supported by grants from the Deutsche Kinderkrebsstiftung to WW (DKS 2014.11, 2016.24, 2018.21, 2020.15).",

year = "2023",

month = may,

doi = "10.3324/haematol.2022.281896",

language = "English",

volume = "108",

pages = "1442--1446",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "5",

}

Knörr, F, Schellekens, KPJ, Schoot, RA, Landman-Parker, J, Teltschik, HM, Förster, J, Riquelme, A, Huitema, ADR, van Eijkelenburg, NKA, Beishuizen, A, Zwaan, CM, Woessmann, W & van der Lugt, J 2023, 'Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma', Haematologica, vol. 108, no. 5, pp. 1442-1446. https://doi.org/10.3324/haematol.2022.281896

TY - JOUR

T1 - Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

AU - Knörr, Fabian

AU - Schellekens, Kim P.J.

AU - Schoot, Reineke A.

AU - Landman-Parker, Judith

AU - Teltschik, Heiko Manuel

AU - Förster, Jan

AU - Riquelme, Amambay

AU - Huitema, Alwin D.R.

AU - van Eijkelenburg, Natasha K.A.

AU - Beishuizen, Auke

AU - Zwaan, C. Michel

AU - Woessmann, Wilhelm

AU - van der Lugt, Jasper

N1 - Funding Information: KS, RS, AH, NvE, CMZ, AB and JvdL received institutional funding from Pfizer. FK, HT, AR, JF, JLP and WW have no conflicts of interest to declare. Funding Information: Pfizer Inc. provided funding and a clinical research collaboration to implement the CRISP trial. The CRISP trial was sponsored by Erasmus MC Sophia Children’s Hospital, Department of Pediatrics, Rotterdam, The Netherlands, and was funded by the Erasmus MC Vriendenfonds Funding Information: Pfizer Inc. provided funding and a clinical research collaboration to implement the CRISP trial. The CRISP trial was sponsored by Erasmus MC Sophia Children’s Hospital, Department of Pediatrics, Rotterdam, The Netherlands, and was funded by the Erasmus MC Vriendenfonds (now Erasmus MC Foundation), Pfizer and Go4Children to CMZ. The NHL-BFM Registry 2012 was supported by grants from the Deutsche Kinderkrebsstiftung to WW (DKS 2014.11, 2016.24, 2018.21, 2020.15).

PY - 2023/5

Y1 - 2023/5

UR - https://www.scopus.com/pages/publications/85147832494

U2 - 10.3324/haematol.2022.281896

DO - 10.3324/haematol.2022.281896

M3 - Letter

C2 - 36519329

AN - SCOPUS:85147832494

SN - 0390-6078

VL - 108

SP - 1442

EP - 1446

JO - Haematologica

JF - Haematologica

IS - 5

ER -

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Access to Document

Other files and links

Cite this